English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

High levels of plasmatic branched‐chain amino acids (BCAA), commonly used as dietary supplements, are linked to metabolic risk factors for Alzheimer's disease (AD). BCAA directly influence amino acid transport to the brain and, therefore, neurotransmitter levels. We thus investigated the impact of BCAA on AD neuropathology in a mouse model.    Methods  3xTg‐AD mice were fed either a control diet or a high‐fat diet from 6 to 18 months of age. For the last 2 months, dietary BCAA content was adjusted to high (+50%), normal (+0%), or low (−50%).    Results  Mice fed a BCAA‐supplemented high‐fat diet displayed higher tau neuropathology and only four out of 13 survived. Mice on the low‐BCAA diet showed higher threonine and tryptophan cortical levels while performing better on the novel object recognition task.    Discussion  These preclinical data underscore a potential risk of combining high‐fat and high BCAA consumption, and possible benefits from BCAA restriction in AD.

Dietary intake of branched‐chain amino acids in a mouse model of Alzheimer's disease: Effects on survival, behavior, and neuropathology